Sylvester Comprehensive Cancer Center

  • 20240173 - Hoffman James

  • Investigator:
    James Hoffman
    RCname Email

    		Coordinator:

    IRB: 20240173

    		SDG: Not Mapped
    Disease Site(s):

    Brain and Nervous System,Kidney,Liver,Multiple Myeloma
    Sponsor: SWOG

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Sylvester
    UMH
    Title:

    A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis
    Eligibility Criteria - NCT06022939 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221372 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    		Coordinator:

    IRB: 20221372

    		SDG: Not Mapped
    Disease Site(s):

    Melanoma, skin
    Sponsor: IB

    Enrolling Sites:

    ABLEH
    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
    Eligibility Criteria - NCT05361174 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240800 - Traeger Lara

  • Investigator:
    Lara Traeger
    RCname Email

    		Coordinator:

    IRB: 20240800

    		SDG: Not Mapped
    Disease Site(s):

    Multiple
    Sponsor: MASSACHUSETTS GENERAL HOSPITAL

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    Multi-Site Randomized Controlled Trial of a Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant
    Eligibility Criteria - NCT06541002 *This information has been extracted from " www.clinicaltrials.gov"

  • INCB057643 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    		Coordinator:

    IRB: 20200314

    		SDG: Not Mapped
    Disease Site(s):

    Other Hematopoietic
    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
    Eligibility Criteria - NCT04279847 *This information has been extracted from " www.clinicaltrials.gov"